Dashboard
Biotech catalyst command center
Watchlist companies
8
Free tier limit is 5
Next 30 days
2
Near-term events
Next 90 days
4
Quarter view
Recent updates
4
Detected changes
Catalyst calendar
Jun 28
GMAB
Conference update on combination cohorts
Jul 10
RVMD
RAS(ON) inhibitor expansion cohort update
Jul 24
ALLO
Cell therapy pipeline investor update
Aug 15
RCUS
STAR-221 interim analysis window
Sep 30
EXEL
STELLAR pivotal study top-line data
Oct 1
MRUS
Combination cohort clinical update
Nov 20
NUVL
Potential regulatory action window
Dec 15
AVBP
ClinicalTrials.gov primary completion watch
Recent changes feed
Clinical trial completion date changed
6/15/2026
primary_completion_date: 2026-10-31 -> 2026-12-15
Status updated
6/15/2026
status: unknown -> upcoming
Press release posted
6/14/2026
press_release: none -> Investor update announced
Catalyst date changed
6/10/2026
expected_period_text: 2H 2026 -> July 2026
Watchlist company table
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| GMAB Genmab | Conference update on combination cohorts ASCO | Epcoritamab | Approved/Phase 3 | ASCO 2026 | exact | upcoming |
| RVMD Revolution Medicines | RAS(ON) inhibitor expansion cohort update Phase 2 Readout | RMC-6236 | Phase 2 | July 2026 | month | active |
| ALLO Allogene Therapeutics | Cell therapy pipeline investor update Investor Day | Cema-cel | Phase 2 | July 24, 2026 | exact | upcoming |
| RCUS Arcus Biosciences | STAR-221 interim analysis window Phase 3 Readout | Domvanalimab | Phase 3 | Q3 2026 | quarter | upcoming |
| EXEL Exelixis | STELLAR pivotal study top-line data Phase 3 Readout | Zanzalintinib | Phase 3 | 2H 2026 | half year | upcoming |
| MRUS Merus | Combination cohort clinical update Phase 2 Readout | Petosemtamab | Phase 2 | Q4 2026 | quarter | upcoming |
| NUVL Nuvalent | Potential regulatory action window FDA PDUFA | Zidesamtinib | Registration | Q4 2026 | quarter | upcoming |
| AVBP ArriVent BioPharma | ClinicalTrials.gov primary completion watch Clinical Trial Completion | Furmonertinib | Phase 3 | December 2026 | month | active |